ACOR Share Price

Open 19.20 Change Price %
High 19.55 1 Day -0.15 -0.78
Low 19.05 1 Week 0.35 1.87
Close 19.05 1 Month 4.80 33.68
Volume 826154 1 Year -6.26 -24.73
52 Week High 33.00
52 Week Low 13.60
ACOR Important Levels
Resistance 2 19.51
Resistance 1 19.32
Pivot 19.22
Support 1 18.78
Support 2 18.59
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.22 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
QQQ 138.03 -1.81%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SMSI 1.62 24.62%
CGEI 0.22 22.22%
THTI 0.20 17.65%
MYRX 0.07 16.67%
BDMS 13.50 16.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Acorda Therapeutics, Inc. (NASDAQ: ACOR)

ACOR Technical Analysis 2
As on 27th Jun 2017 ACOR Share Price closed @ 19.05 and we RECOMMEND Sell for LONG-TERM with Stoploss of 21.03 & Strong Buy for SHORT-TERM with Stoploss of 16.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACOR Target for June
1st Target up-side 15.56
2nd Target up-side 16.79
3rd Target up-side 18.03
1st Target down-side 12.04
2nd Target down-side 10.81
3rd Target down-side 9.57
ACOR Other Details
Segment EQ
Market Capital 995115008.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.acorda.com
ACOR Address
ACOR
420 Saw Mill River Road
Ardsley, NY 10502
United States
Phone: 914-347-4300
Fax: 914-347-4560
ACOR Latest News
Interactive Technical Analysis Chart Acorda Therapeutics, Inc. ( ACOR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Acorda Therapeutics, Inc.
ACOR Business Profile
Acorda Therapeutics, Inc. (Acorda), incorporated on March 17, 1995, is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.